WuXi STA Enhances Changzhou Campus Peptide Manufacturing Capacity

WuXi STA, a global contract research, development, and manufacturing organisation (CRDMO), has expanded its Changzhou campus with two 2,000 L reactors and a large-scale continuous purification system for peptide manufacturing. The new additions expand WuXi TIDES' capability and capacity. WuXi TIDES is an end-to-end CRDMO platform for oligonucleotide, peptide, and related synthetic conjugates (TIDES drugs) that is an integral part of WuXi STA, simplifying TIDES drug development by bringing all discovery, CMC development, and the manufacturing supply chain under one roof.

With the addition of two new 2,000 L reactors, the total reactor volume of the Solid Phase Peptide Synthesizers (SPPS) at WuXi TIDES has risen to more than 10,000 L. Along with the increased peptide capacity, WuXi TIDES has added a new continuous purification system with 300-DAC twin columns for continuous purification of kilogramme-scale peptide and oligonucleotide. Continuous mode purification allows for a faster turnaround time and lower solvent consumption, allowing for more efficient and sustainable peptide and oligonucleotide manufacturing.